insulin + dapagliflozin + metformin

insulin + dapagliflozin + metformin is a triple combination therapy used for the management of type 2 diabetes mellitus (T2DM). This regimen integrates three distinct pharmacological approaches: insulin, which acts as an exogenous replacement for the hormone to facilitate glucose uptake; dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption and promotes its excretion in the urine; and metformin, a biguanide that decreases hepatic glucose production and enhances insulin sensitivity. This combination is particularly investigated for patients who fail to achieve glycemic targets on dual therapy or insulin-based regimens. Research conducted by institutions like The First People's Hospital of Xuzhou has focused on the efficacy of this triple therapy in improving HbA1c levels, reducing body weight, and minimizing the risk of hypoglycemia compared to intensive insulin therapy alone.

Other names

dapagliflozin + metformin + insulininsulin, dapagliflozin, and metformin combination